secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001558370-23-016235
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte preliminary Q3 revenue $7.8-8.0M; cuts FY2023 revenue guidance to $34-36M
--------------------------------------------------------------------------------

- Q3 total revenue expected $7.8-8.0M, down 25-27% YoY; core revenue $6.4-6.6M, down 33-35% YoY.
- FY2023 total revenue guidance reduced to ~$34-36M; core revenue guidance lowered to $28-30M.
- SPL program-related revenue Q3 $1.4M vs $0.8M YoY; full-year SPL guidance unchanged at ~$6M.
- Company cites depressed cell and gene therapy funding, customer inventory, and elongation of preclinical activity.
- Ending cash expected ~$200M, unchanged from initial 2023 outlook.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023016235/0001558370-23-016235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023016235/mxct-20231004x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer